Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

Trial Profile

A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs ABBV 176 (Primary)
  • Indications Adrenocortical carcinoma; Breast cancer; Colorectal cancer; Liver cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 28 Nov 2018 Status changed from suspended to discontinued.
    • 28 Aug 2018 Status changed from recruiting to suspended due to safety issues.
    • 20 Jul 2018 Planned number of patients changed from 100 to 120.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top